Another candidate that is potentially applicable to NAFLD treatment [53] is a drug combination (HM14320) consisting of HM15136 (a glucagon analog) and efpeglenatide (a GLP-1 analog), but there are no published studies regarding the combination’s effectiveness. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.